RecruitingNCT05828628

CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study

A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers


Sponsor

Royal Marsden NHS Foundation Trust

Enrollment

36 participants

Start Date

Sep 18, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1)
  • A radiological or histological diagnosis of primary CNS lymphoma.
  • Have not received prior CNS directed therapy. Prior use of steroids is permitted.
  • Participants aged ≥18 years old.

Exclusion Criteria1

  • \- Involvement of lymphoma outside of the CNS

Locations(1)

The Royal Marsden NHS Foundation Trust, Downs Road

Sutton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05828628


Related Trials